A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma.

Abstract

10024 Background: TH-302 is a 2-nitroimidazole prodrug of the DNA alkylator, bromo-isophosphoramide mustard. TH-302 is designed for activation in severe hypoxia, releasing Br-IPM. The MTD of TH-302 in combination with doxorubicin (Dox) was established at 300 mg/m2. A Phase II expansion at the MTD investigated the activity and safety of TH-302 in combination… (More)

Topics

Cite this paper

@article{Cranmer2011API, title={A phase II dose expansion of TH-302 in combination with doxorubicin in soft-tissue sarcoma.}, author={L. D. Cranmer and Kristen N Ganjoo and D. Adkins and Dan Reed and Shin’ya Okuno and James E. Butrynski and Darrien Rushing and Gustavo Angel Lorente and S. Kroll and Sant P. Chawla}, journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology}, year={2011}, volume={29 15_suppl}, pages={10024} }